Miguel Sanchez-Almira
Geriatric Psychiatry · Brooklyn, NYNPI 1922206945
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Alkermes, Inc. at 24.6% of the total.
Across 201 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$692
- Teva Pharmaceuticals USA, Inc.$647
- Otsuka America Pharmaceutical, Inc.$439
- E.r. Squibb & Sons, L.L.C.$195
- plus $383 from 7 others
What the payments were for
- Food & beverage$4,574100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 49 | $1,123 |
| Johnson & Johnson | 52 | $1,096 |
| Neurocrine Biosciences, Inc. | 27 | $692 |
| Teva Pharmaceuticals USA, Inc. | 27 | $647 |
| Otsuka America Pharmaceutical, Inc. | 21 | $439 |
| E.r. Squibb & Sons, L.L.C. | 7 | $195 |
| Lundbeck LLC | 6 | $152 |
| Sunovion Pharmaceuticals Inc. | 7 | $111 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Corium, LLC | 1 | $25 |
| AbbVie | 1 | $24 |
| Bioxcel Therapeutics, Inc. | 1 | $24 |
| Indivior Inc. | 1 | $20 |
How this compares
$4,574 in reported general payments places this provider in the 85th percentile of 45 geriatric psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 34 | $89,734 |
| Invega SustennaPaliperidone Palmitate | 18 | $38,408 |
| Risperdal ConstaRisperidone Microspheres | 12 | $13,804 |
| Buspirone Hcl | 339 | $2,518 |
| Aripiprazole | 203 | $2,339 |
| Mirtazapine | 281 | $1,955 |
| Trazodone Hcl | 311 | $1,206 |
| Quetiapine Fumarate | 163 | $1,018 |
| Sertraline Hcl | 195 | $832 |
| Risperidone | 153 | $772 |
| Haloperidol | 39 | $724 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 85 | $698 |
| Escitalopram Oxalate | 231 | $660 |
| Divalproex Sodium | 39 | $635 |
| Divalproex Sodium ErDivalproex Sodium | 44 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $439 | $89,73434 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $1,096 | $52,21230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 geriatric psychiatry providers in New York.
Other geriatric psychiatry in Brooklyn
- Mario GustaveBrooklyn$766
- Dipaloke BanikBrooklyn$270
- Francis RathinapandianBrooklyn$32
- William FlorioBrooklyn$23
- Davangere DevanandBinghamton$137K
- Diane AnnalettBuffalo$12K
- Roberto EstradaNew York$8K
- Alan SteinbergCentereach$8K
- Istvan BoksayNew York$8K
- Barry ReisbergNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.